mr ARIEL GONZALEZ esq

Artificial intelligence policy, deepfake policy, and national security policy. Example bills: Preventing Deepfakes of Intimate Images Act (HR 3106), DEEPFAKES Accountability Act (HR 5586), NO FAKES Act (draft bill, Senate), and the NO AI FRAUD Act (HR 6943).

Artificial intelligence policy, deepfake policy, and national security policy. Example bills: Preventing Deepfakes of Intimate Images Act (HR 3106), DEEPFAKES Accountability Act (HR 5586), NO FAKES Act (draft bill, Senate), and the NO AI FRAUD Act (HR 6943).

Artificial intelligence policy, deepfake policy, and national security policy. Example bills: Preventing Deepfakes of Intimate Images Act (HR 3106), DEEPFAKES Accountability Act (HR 5586), NO FAKES Act (draft bill, Senate), and the NO AI FRAUD Act (HR 6943).

Artificial intelligence policy, deepfake policy, and national security policy. Example bills: Preventing Deepfakes of Intimate Images Act (HR 3106), DEEPFAKES Accountability Act (HR 5586), NO FAKES Act (draft bill, Senate), and the NO AI FRAUD Act (HR 6943).

Artificial intelligence policy, deepfake policy, and national security policy. Example bills: Preventing Deepfakes of Intimate Images Act (HR 3106), DEEPFAKES Accountability Act (HR 5586), NO FAKES Act (draft bill, Senate), and the NO AI FRAUD Act (HR 6943).

Artificial intelligence policy, deepfake policy, and national security policy. Example bills: Preventing Deepfakes of Intimate Images Act (HR 3106), DEEPFAKES Accountability Act (HR 5586), NO FAKES Act (draft bill, Senate), and the NO AI FRAUD Act (HR 6943).

Artificial intelligence policy, deepfake policy, and national security policy. Example bills: Preventing Deepfakes of Intimate Images Act (HR 3106), DEEPFAKES Accountability Act (HR 5586), NO FAKES Act (draft bill, Senate), and the NO AI FRAUD Act (HR 6943).

Artificial intelligence policy, deepfake policy, and national security policy. Example bills: Preventing Deepfakes of Intimate Images Act (HR 3106), DEEPFAKES Accountability Act (HR 5586), NO FAKES Act (draft bill, Senate), and the NO AI FRAUD Act (HR 6943).

Artificial intelligence policy, deepfake policy, and national security policy. Example bills: Preventing Deepfakes of Intimate Images Act (HR 3106), DEEPFAKES Accountability Act (HR 5586), NO FAKES Act (draft bill, Senate), and the NO AI FRAUD Act (HR 6943).

Artificial intelligence policy, deepfake policy, and national security policy. Example bills: Preventing Deepfakes of Intimate Images Act (HR 3106), DEEPFAKES Accountability Act (HR 5586), NO FAKES Act (draft bill, Senate), and the NO AI FRAUD Act (HR 6943).

Artificial intelligence policy, deepfake policy, and national security policy. Example bills: Preventing Deepfakes of Intimate Images Act (HR 3106), DEEPFAKES Accountability Act (HR 5586), NO FAKES Act (draft bill, Senate), and the NO AI FRAUD Act (HR 6943).

Issues pertaining to physician payment and quality measurement, including HR 2474, Strengthening Medicare for Patients and Providers Act; observation care, including HR 5138, Improving Access to Medicare Coverage Act of 2023; prior authorization and access to care through Medicare Advantage

S 2768/HR 2584, Safety From Violence for Healthcare Employees Act

Policies related to employment-based immigration for physicians, including S. 655/HR 4942 Conrad State 30 and Physician Access Reauthorization Act

Issues pertaining to physician payment and quality measurement, including HR 2474, Strengthening Medicare for Patients and Providers Act; observation care, including HR 5138, Improving Access to Medicare Coverage Act of 2023; prior authorization and access to care through Medicare Advantage

S 2768/HR 2584, Safety From Violence for Healthcare Employees Act

Policies related to employment-based immigration for physicians, including S. 655/HR 4942 Conrad State 30 and Physician Access Reauthorization Act

Issues generally related to biopharmaceutical drugs and drug development programs, including, but not limited to: Orphan Drug Act incentives, including H.R. 1629/S.250, the Fairness in Orphan Drug Exclusivity Act; drug pricing proposals, including H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act and H.R. 19/S.2164, Lower Costs, More Cures Act of 2021; access to rare disease and gene therapy drugs; FDA approvals of drugs designed to treat rare diseases, including gene therapies; and regulatory reforms generally, including but not limited to S. 3799, the PREVENT Pandemics Act, H.R. 6000, CURES 2.0, H.R. 6963, the Accelerated Approval Integrity Act of 2022, H.R. 6996, the Accelerating Access for Patients Act. Issues pertaining to newborn screening and gene panel screening, including provisions of H.R. 482/S.350 , the Newborn Screening Saves Lives Reauthorization Act of 2021. Policies contained in and amendments offered to S.Con.Res.5, setting forth the congressional budget for the United States Government for fiscal year 2021 and setting forth the appropriate budgetary levels for fiscal years 2022 through 2030; and policies contained in and amendments offered to P.L. 117-2, the American Rescue Plan Act of 2021.

Issues generally related to biopharmaceutical drugs and drug development programs, including, but not limited to: Orphan Drug Act incentives, including H.R. 1629/S.250, the Fairness in Orphan Drug Exclusivity Act; drug pricing proposals, including H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act and H.R. 19/S.2164, Lower Costs, More Cures Act of 2021; access to rare disease and gene therapy drugs; education and awareness of genetic rare bone disorders; FDA approvals of drugs designed to treat rare diseases, including gene therapies; and regulatory reforms generally, including but not limited to S. 3799, the PREVENT Pandemics Act, H.R. 6000, CURES 2.0, H.R. 6963, the Accelerated Approval Integrity Act of 2022, H.R. 6996, the Accelerating Access for Patients Act; H.R. 7667, Food and Drug Amendments of 2022, and S. 4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act. Issues pertaining to newborn screening and gene panel screening, including provisions of H.R. 482/S.350 , the Newborn Screening Saves Lives Reauthorization Act of 2021. Policies contained in and amendments offered to S.Con.Res.5, setting forth the congressional budget for the United States Government for fiscal year 2021 and setting forth the appropriate budgetary levels for fiscal years 2022 through 2030; and policies contained in and amendments offered to P.L. 117-2, the American Rescue Plan Act of 2021.

Issues generally related to biopharmaceutical drugs and drug development programs, including but not limited to drug pricing proposals, Medicaid payments, and access to rare disease and gene therapy drugs. Policies contained in drug pricing proposals, including H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act and H.R. 19/S.2164, Lower Costs, More Cures Act of 2021, and in H.R.3684 - Infrastructure Investment and Jobs Act and H.R. 5376, Build Back Better Act. Policies contained in 85 FR 87000, Medicaid Program; Establishing Minimum Standards in Medicaid State Drug Utilization Review (DUR) and Supporting Value-Based Purchasing (VBP) for Drugs Covered in Medicaid, Revising Medicaid Drug Rebate and Third Party Liability (TPL) Requirements.

Issues generally related to biopharmaceutical drugs and drug development programs, including, but not limited to: Orphan Drug Act incentives, including H.R. 1629/S.250, the Fairness in Orphan Drug Exclusivity Act; drug pricing proposals, including H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act and H.R. 19/S.2164, Lower Costs, More Cures Act of 2021; access to rare disease and gene therapy drugs; education and awareness of genetic rare bone disorders; FDA approvals of drugs designed to treat rare diseases, including gene therapies; and regulatory reforms generally, including but not limited to S. 3799, the PREVENT Pandemics Act, H.R. 6000, CURES 2.0, H.R. 6963, the Accelerated Approval Integrity Act of 2022, H.R. 6996, the Accelerating Access for Patients Act; H.R. 7667, Food and Drug Amendments of 2022, and S. 4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act. Issues pertaining to newborn screening and gene panel screening, including provisions of H.R. 482/S.350 , the Newborn Screening Saves Lives Reauthorization Act of 2021. Policies contained in and amendments offered to S.Con.Res.5, setting forth the congressional budget for the United States Government for fiscal year 2021 and setting forth the appropriate budgetary levels for fiscal years 2022 through 2030; and policies contained in and amendments offered to P.L. 117-2, the American Rescue Plan Act of 2021.

Issues generally related to biopharmaceutical drugs and drug development programs, including but not limited to drug pricing proposals, Medicaid payments, access to treatment through telehealth, and access to rare disease and gene therapy drugs. Policies contained in drug pricing proposals, including H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act and H.R. 19/S.2164, Lower Costs, More Cures Act of 2021. Policies contained in 85 FR 87000, Medicaid Program; Establishing Minimum Standards in Medicaid State Drug Utilization Review (DUR) and Supporting Value-Based Purchasing (VBP) for Drugs Covered in Medicaid, Revising Medicaid Drug Rebate and Third Party Liability (TPL) Requirements. H.R. 7489, Medicaid VBPs for Patients Act or the MVP Act.

Issues generally related to biopharmaceutical drugs and drug development programs, including but not limited to drug pricing proposals, Medicaid payments, access to treatment through telehealth, and access to rare disease and gene therapy drugs. Policies contained in drug pricing proposals, including H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act and H.R. 19/S.2164, Lower Costs, More Cures Act of 2021. Policies contained in 85 FR 87000, Medicaid Program; Establishing Minimum Standards in Medicaid State Drug Utilization Review (DUR) and Supporting Value-Based Purchasing (VBP) for Drugs Covered in Medicaid, Revising Medicaid Drug Rebate and Third Party Liability (TPL) Requirements. H.R. 7489, Medicaid VBPs for Patients Act or the MVP Act.

Issues generally related to biopharmaceutical drugs and drug development programs, including but not limited to drug pricing proposals, Medicaid payments, access to treatment through telehealth, and access to rare disease and gene therapy drugs. Policies contained in drug pricing proposals, including H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act and H.R. 19/S.2164, Lower Costs, More Cures Act of 2021, and in H.R.3684 - Infrastructure Investment and Jobs Act and H.R. 5376, Build Back Better Act. Policies contained in 85 FR 87000, Medicaid Program; Establishing Minimum Standards in Medicaid State Drug Utilization Review (DUR) and Supporting Value-Based Purchasing (VBP) for Drugs Covered in Medicaid, Revising Medicaid Drug Rebate and Third Party Liability (TPL) Requirements. H.R. 7489, Medicaid VBPs for Patients Act or the MVP Act.

Issues generally related to biopharmaceutical drugs and drug development programs, including, but not limited to: Orphan Drug Act incentives, including H.R. 1629/S.250, the Fairness in Orphan Drug Exclusivity Act; drug pricing proposals, including H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act and H.R. 19/S.2164, Lower Costs, More Cures Act of 2021; access to rare disease and gene therapy drugs; FDA approvals of drugs designed to treat rare diseases, including gene therapies; and regulatory reforms generally, including but not limited to S. 3799, the PREVENT Pandemics Act, H.R. 6000, CURES 2.0, H.R. 6963, the Accelerated Approval Integrity Act of 2022, H.R. 6996, the Accelerating Access for Patients Act. Issues pertaining to newborn screening and gene panel screening, including provisions of H.R. 482/S.350 , the Newborn Screening Saves Lives Reauthorization Act of 2021. Policies contained in and amendments offered to S.Con.Res.5, setting forth the congressional budget for the United States Government for fiscal year 2021 and setting forth the appropriate budgetary levels for fiscal years 2022 through 2030; and policies contained in and amendments offered to P.L. 117-2, the American Rescue Plan Act of 2021.

H.R. 2255/S.1024, Healthcare Workforce Resilience Act; H.R. 3648, Equal Access to Green cards for Legal Employment Act of 2021 or the EAGLE Act of 2021; H.R. 3541/S. 1810, Conrad State 30 and Physician Access Reauthorization Act; policies contained in H.R. 5376, to provide for reconciliation pursuant to title II of S. Con. Res. 14.

H.R. 2255/ S.1024-Healthcare Workforce Resilience Act; H.R. 3648, Equal Access to Green cards for Legal Employment Act of 2021 or the EAGLE Act of 2021; and H.R. 3541/S. 1810, Conrad State 30 and Physician Access Reauthorization Act; policies contained in H.R. 5376, to provide for reconciliation pursuant to title II of S. Con. Res. 14.

H.R. 2255/ S.1024-Healthcare Workforce Resilience Act; H.R. 3648, Equal Access to Green cards for Legal Employment Act of 2021 or the EAGLE Act of 2021; and H.R. 3541/S. 1810, Conrad State 30 and Physician Access Reauthorization Act; policies contained in H.R. 5376, to provide for reconciliation pursuant to title II of S. Con. Res. 14.

H.R. 2255/ S.1024-Healthcare Workforce Resilience Act; H.R. 3648, Equal Access to Green cards for Legal Employment Act of 2021 or the EAGLE Act of 2021; and H.R. 3541/S. 1810, Conrad State 30 and Physician Access Reauthorization Act; policies contained in H.R. 5376, to provide for reconciliation pursuant to title II of S. Con. Res. 14.

Issues generally related to biopharmaceutical drugs and drug development programs, including, but not limited to: Orphan Drug Act incentives, including H.R. 1629/S.250, the Fairness in Orphan Drug Exclusivity Act; drug pricing proposals, including H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act and H.R. 19/S.2164, Lower Costs, More Cures Act of 2021; access to rare disease and gene therapy drugs; education and awareness of genetic rare bone disorders; FDA approvals of drugs designed to treat rare diseases, including gene therapies; and regulatory reforms generally, including but not limited to S. 3799, the PREVENT Pandemics Act, H.R. 6000, CURES 2.0, H.R. 6963, the Accelerated Approval Integrity Act of 2022, H.R. 6996, the Accelerating Access for Patients Act; H.R. 7667, Food and Drug Amendments of 2022, and S. 4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act. Issues pertaining to newborn screening and gene panel screening, including provisions of H.R. 482/S.350 , the Newborn Screening Saves Lives Reauthorization Act of 2021. Policies contained in and amendments offered to S.Con.Res.5, setting forth the congressional budget for the United States Government for fiscal year 2021 and setting forth the appropriate budgetary levels for fiscal years 2022 through 2030; and policies contained in and amendments offered to P.L. 117-2, the American Rescue Plan Act of 2021.

Issues generally related to biopharmaceutical drugs and drug development programs, including but not limited to drug pricing proposals, Medicaid payments, access to treatment through telehealth, and access to rare disease and gene therapy drugs. Policies contained in drug pricing proposals, including H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act and H.R. 19/S.2164, Lower Costs, More Cures Act of 2021, and in H.R.3684 - Infrastructure Investment and Jobs Act and H.R. 5376, Build Back Better Act. Policies contained in 85 FR 87000, Medicaid Program; Establishing Minimum Standards in Medicaid State Drug Utilization Review (DUR) and Supporting Value-Based Purchasing (VBP) for Drugs Covered in Medicaid, Revising Medicaid Drug Rebate and Third Party Liability (TPL) Requirements. H.R. 7489, Medicaid VBPs for Patients Act or the MVP Act.

Issues generally related to biopharmaceutical drugs and drug development programs, including but not limited to drug pricing proposals, Medicaid payments, access to treatment through telehealth, and access to rare disease and gene therapy drugs. Policies contained in drug pricing proposals, including H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act and H.R. 19/S.2164, Lower Costs, More Cures Act of 2021. Policies contained in 85 FR 87000, Medicaid Program; Establishing Minimum Standards in Medicaid State Drug Utilization Review (DUR) and Supporting Value-Based Purchasing (VBP) for Drugs Covered in Medicaid, Revising Medicaid Drug Rebate and Third Party Liability (TPL) Requirements. H.R. 7489, Medicaid VBPs for Patients Act or the MVP Act.

Issues generally related to biopharmaceutical drugs and drug development programs, including but not limited to drug pricing proposals, Medicaid payments, access to treatment through telehealth, and access to rare disease and gene therapy drugs. Policies contained in drug pricing proposals, including H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act and H.R. 19/S.2164, Lower Costs, More Cures Act of 2021. Policies contained in 85 FR 87000, Medicaid Program; Establishing Minimum Standards in Medicaid State Drug Utilization Review (DUR) and Supporting Value-Based Purchasing (VBP) for Drugs Covered in Medicaid, Revising Medicaid Drug Rebate and Third Party Liability (TPL) Requirements. H.R. 7489, Medicaid VBPs for Patients Act or the MVP Act.

Issues generally related to biopharmaceutical drugs and drug development programs, including but not limited to drug pricing proposals, Medicaid payments, and access to rare disease and gene therapy drugs. Policies contained in drug pricing proposals, including H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act and H.R. 19/S.2164, Lower Costs, More Cures Act of 2021, and in H.R.3684 - Infrastructure Investment and Jobs Act and H.R. 5376, Build Back Better Act. Policies contained in 85 FR 87000, Medicaid Program; Establishing Minimum Standards in Medicaid State Drug Utilization Review (DUR) and Supporting Value-Based Purchasing (VBP) for Drugs Covered in Medicaid, Revising Medicaid Drug Rebate and Third Party Liability (TPL) Requirements.

Issues generally related to biopharmaceutical drugs and drug development programs, including, but not limited to: Orphan Drug Act incentives, including H.R. 1629/S.250, the Fairness in Orphan Drug Exclusivity Act; drug pricing proposals, including H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act and H.R. 19/S.2164, Lower Costs, More Cures Act of 2021; access to rare disease and gene therapy drugs; FDA approvals of drugs designed to treat rare diseases, including gene therapies; and regulatory reforms generally, including but not limited to S. 3799, the PREVENT Pandemics Act, H.R. 6000, CURES 2.0, H.R. 6963, the Accelerated Approval Integrity Act of 2022, H.R. 6996, the Accelerating Access for Patients Act. Issues pertaining to newborn screening and gene panel screening, including provisions of H.R. 482/S.350 , the Newborn Screening Saves Lives Reauthorization Act of 2021. Policies contained in and amendments offered to S.Con.Res.5, setting forth the congressional budget for the United States Government for fiscal year 2021 and setting forth the appropriate budgetary levels for fiscal years 2022 through 2030; and policies contained in and amendments offered to P.L. 117-2, the American Rescue Plan Act of 2021.

H.R. 2255/ S.1024-Healthcare Workforce Resilience Act; H.R. 3648, Equal Access to Green cards for Legal Employment Act of 2021 or the EAGLE Act of 2021; and H.R. 3541/S. 1810, Conrad State 30 and Physician Access Reauthorization Act; policies contained in H.R. 5376, to provide for reconciliation pursuant to title II of S. Con. Res. 14.

H.R. 2255/ S.1024-Healthcare Workforce Resilience Act; H.R. 3648, Equal Access to Green cards for Legal Employment Act of 2021 or the EAGLE Act of 2021; and H.R. 3541/S. 1810, Conrad State 30 and Physician Access Reauthorization Act; policies contained in H.R. 5376, to provide for reconciliation pursuant to title II of S. Con. Res. 14.

H.R. 2255/S.1024, Healthcare Workforce Resilience Act; H.R. 3648, Equal Access to Green cards for Legal Employment Act of 2021 or the EAGLE Act of 2021; H.R. 3541/S. 1810, Conrad State 30 and Physician Access Reauthorization Act; policies contained in H.R. 5376, to provide for reconciliation pursuant to title II of S. Con. Res. 14.

H.R. 2255/ S.1024-Healthcare Workforce Resilience Act; H.R. 3648, Equal Access to Green cards for Legal Employment Act of 2021 or the EAGLE Act of 2021; and H.R. 3541/S. 1810, Conrad State 30 and Physician Access Reauthorization Act; policies contained in H.R. 5376, to provide for reconciliation pursuant to title II of S. Con. Res. 14.

H.R. 2255/S.1024, Healthcare Workforce Resilience Act; H.R. 3648, Equal Access to Green cards for Legal Employment Act of 2021 or the EAGLE Act of 2021; H.R. 3541/S. 1810, Conrad State 30 and Physician Access Reauthorization Act; policies contained in H.R. 5376, to provide for reconciliation pursuant to title II of S. Con. Res. 14.

H.R. 2255/ S.1024-Healthcare Workforce Resilience Act; H.R. 3648, Equal Access to Green cards for Legal Employment Act of 2021 or the EAGLE Act of 2021; and H.R. 3541/S. 1810, Conrad State 30 and Physician Access Reauthorization Act; policies contained in H.R. 5376, to provide for reconciliation pursuant to title II of S. Con. Res. 14.

H.R. 2255/ S.1024-Healthcare Workforce Resilience Act; H.R. 3648, Equal Access to Green cards for Legal Employment Act of 2021 or the EAGLE Act of 2021; and H.R. 3541/S. 1810, Conrad State 30 and Physician Access Reauthorization Act; policies contained in H.R. 5376, to provide for reconciliation pursuant to title II of S. Con. Res. 14.

H.R. 2255/ S.1024-Healthcare Workforce Resilience Act; H.R. 3648, Equal Access to Green cards for Legal Employment Act of 2021 or the EAGLE Act of 2021; and H.R. 3541/S. 1810, Conrad State 30 and Physician Access Reauthorization Act; policies contained in H.R. 5376, to provide for reconciliation pursuant to title II of S. Con. Res. 14.

Policies that affect hospitals in P.L. 117-103, the Consolidated Appropriations Act, 2022, H.R.3684, Infrastructure Investment and Jobs Act and H.R. 5376, to provide for reconciliation pursuant to title II of S. Con. Res. 14.

Issues generally related to biopharmaceutical drugs and drug development programs, including but not limited to drug pricing proposals, Medicaid payments, and access to rare disease and gene therapy drugs. Policies contained in drug pricing proposals, including H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act and H.R. 19/S.2164, Lower Costs, More Cures Act of 2021, and in H.R.3684 - Infrastructure Investment and Jobs Act and H.R. 5376, Build Back Better Act. Policies contained in 85 FR 87000, Medicaid Program; Establishing Minimum Standards in Medicaid State Drug Utilization Review (DUR) and Supporting Value-Based Purchasing (VBP) for Drugs Covered in Medicaid, Revising Medicaid Drug Rebate and Third Party Liability (TPL) Requirements.

Policies that affect hospitals and skilled nursing facilities in P.L. 117-103, the Consolidated Appropriations Act, 2022,, H.R.3684, Infrastructure Investment and Jobs Act and H.R. 5376, to provide for reconciliation pursuant to title II of S. Con. Res. 14; various value-based payment models at the Centers for Medicare and Medicaid Innovation.

Policies that affect hospitals and skilled nursing facilities in P.L. 117-103, the Consolidated Appropriations Act, 2022,, H.R.3684, Infrastructure Investment and Jobs Act and H.R. 5376, to provide for reconciliation pursuant to title II of S. Con. Res. 14; various value-based payment models at the Centers for Medicare and Medicaid Innovations.

Issues related generally to: Medicare Advantage, Medicare Part D, and Medicaid managed care plans, including but not limited to policies related to social determinants of health, health equity, and maternal mortality, including policies contained in and amendments offered to S.Con.Res.5, setting forth the congressional budget for the United States Government for fiscal year 2021 and setting forth the appropriate budgetary levels for fiscal years 2022 through 2030; and policies contained in and amendments offered to P.L. 117-2, the American Rescue Plan Act of 2021. Policies contained in P.L. 117-7, to prevent across-the-board direct spending cuts, and for other purposes, and P.L. 117-71, Protecting Medicare and American Farmers from Sequester Cuts Act. Policies contained in H.R.3684 - Infrastructure Investment and Jobs Act, and H.R. 5376, Build Back Better Act.

Policies contained in H.R.3684, Infrastructure Investment and Jobs Act and H.R. 5376, Build Back Better Act.

Issues generally related to biopharmaceutical drugs and drug development programs, including but not limited to drug pricing proposals, Medicaid payments, access to treatment through telehealth, and access to rare disease and gene therapy drugs. Policies contained in drug pricing proposals, including H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act and H.R. 19/S.2164, Lower Costs, More Cures Act of 2021, and in H.R.3684 - Infrastructure Investment and Jobs Act and H.R. 5376, Build Back Better Act. Policies contained in 85 FR 87000, Medicaid Program; Establishing Minimum Standards in Medicaid State Drug Utilization Review (DUR) and Supporting Value-Based Purchasing (VBP) for Drugs Covered in Medicaid, Revising Medicaid Drug Rebate and Third Party Liability (TPL) Requirements. H.R. 7489, Medicaid VBPs for Patients Act or the MVP Act.

Policies contained in H.R.3684, Infrastructure Investment and Jobs Act and H.R. 5376, Build Back Better Act.

Policies that affect hospitals and ambulatory surgery centers in P.L. 117-103, the Consolidated Appropriations Act, 2022, H.R.3684, Infrastructure Investment and Jobs Act and H.R. 5376, to provide for reconciliation pursuant to title II of S. Con. Res. 14.

Issues related generally to: the Affordable Care Act, insurance markets/stabilization, transparency, surprise billing, access to and payment for mental health care, and COVID-19 response, including those contained in but not limited to policies in and amendments offered to S.Con.Res.5, setting forth the congressional budget for the United States Government for fiscal year 2021 and setting forth the appropriate budgetary levels for fiscal years 2022 through 2030, and P.L. 117-103, the Consolidated Appropriations Act, 2022; and health care policies contained in and amendments offered to P.L. 117-2, the American Rescue Plan Act of 2021. Policies contained in H.R.3684 - Infrastructure Investment and Jobs Act, H.R. 5376, Build Back Better Act; H.R. 7666, Restoring Hope for Mental Health and Well Being Act of 2022; and H.R. 5218, Collaborate in an Orderly and Cohesive Manner Act.

Issues related generally to: Medicare Advantage, Medicare Part D, and Medicaid managed care plans, including but not limited to policies related to social determinants of health, health equity, and maternal mortality, including policies contained in and amendments offered to S.Con.Res.5, setting forth the congressional budget for the United States Government for fiscal year 2021 and setting forth the appropriate budgetary levels for fiscal years 2022 through 2030; and policies contained in and amendments offered to P.L. 117-2, the American Rescue Plan Act of 2021. Policies contained in P.L. 117-7, to prevent across-the-board direct spending cuts, and for other purposes, and P.L. 117-71, Protecting Medicare and American Farmers from Sequester Cuts Act. Policies contained in H.R.3684 - Infrastructure Investment and Jobs Act, and H.R. 5376, Build Back Better Act.

Issues related generally to: the Affordable Care Act, insurance markets/stabilization, transparency, surprise billing, access to and payment for mental health care, and COVID-19 response, including those contained in but not limited to policies in and amendments offered to S.Con.Res.5, setting forth the congressional budget for the United States Government for fiscal year 2021 and setting forth the appropriate budgetary levels for fiscal years 2022 through 2030, and P.L. 117-103, the Consolidated Appropriations Act, 2022; and health care policies contained in and amendments offered to P.L. 117-2, the American Rescue Plan Act of 2021. Policies contained in H.R.3684 - Infrastructure Investment and Jobs Act, and H.R. 5376, Build Back Better Act.

General education around paid family, medical and sick leave issues; paid sick day policies in P.L. 117-2, the Consolidated Appropriations Act, 2021, H.R. 804/S. 248, the FAMILY Act; policies contained in H.R.3684, Infrastructure Investment and Jobs Act and H.R. 5376, Build Back Better Act.

Issues generally related to biopharmaceutical drugs and drug development programs, including, but not limited to: Orphan Drug Act incentives, including H.R. 1629/S.250, the Fairness in Orphan Drug Exclusivity Act; drug pricing proposals, including H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act and H.R. 19/S.2164, Lower Costs, More Cures Act of 2021; access to rare disease and gene therapy drugs; FDA approvals of drugs designed to treat rare diseases, including gene therapies; and regulatory reforms generally, including but not limited to S. 3799, the PREVENT Pandemics Act, H.R. 6000, CURES 2.0, H.R. 6963, the Accelerated Approval Integrity Act of 2022, H.R. 6996, the Accelerating Access for Patients Act. Issues pertaining to newborn screening and gene panel screening, including provisions of H.R. 482/S.350 , the Newborn Screening Saves Lives Reauthorization Act of 2021. Policies contained in and amendments offered to S.Con.Res.5, setting forth the congressional budget for the United States Government for fiscal year 2021 and setting forth the appropriate budgetary levels for fiscal years 2022 through 2030; and policies contained in and amendments offered to P.L. 117-2, the American Rescue Plan Act of 2021.

Issues generally related to biopharmaceutical drugs and drug development programs, including, but not limited to: Orphan Drug Act incentives, including H.R. 1629/S.250, the Fairness in Orphan Drug Exclusivity Act; drug pricing proposals, including H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act and H.R. 19/S.2164, Lower Costs, More Cures Act of 2021; access to rare disease and gene therapy drugs; education and awareness of genetic rare bone disorders; FDA approvals of drugs designed to treat rare diseases, including gene therapies; and regulatory reforms generally, including but not limited to S. 3799, the PREVENT Pandemics Act, H.R. 6000, CURES 2.0, H.R. 6963, the Accelerated Approval Integrity Act of 2022, H.R. 6996, the Accelerating Access for Patients Act; H.R. 7667, Food and Drug Amendments of 2022, and S. 4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act. Issues pertaining to newborn screening and gene panel screening, including provisions of H.R. 482/S.350 , the Newborn Screening Saves Lives Reauthorization Act of 2021. Policies contained in and amendments offered to S.Con.Res.5, setting forth the congressional budget for the United States Government for fiscal year 2021 and setting forth the appropriate budgetary levels for fiscal years 2022 through 2030; and policies contained in and amendments offered to P.L. 117-2, the American Rescue Plan Act of 2021.

Issues related generally to: the Affordable Care Act, insurance markets/stabilization, transparency, surprise billing, access to and payment for mental health care, and COVID-19 response, including those contained in but not limited to policies in and amendments offered to S.Con.Res.5, setting forth the congressional budget for the United States Government for fiscal year 2021 and setting forth the appropriate budgetary levels for fiscal years 2022 through 2030, and P.L. 117-103, the Consolidated Appropriations Act, 2022; and health care policies contained in and amendments offered to P.L. 117-2, the American Rescue Plan Act of 2021. Policies contained in H.R.3684 - Infrastructure Investment and Jobs Act, H.R. 5376, Build Back Better Act; H.R. 7666, Restoring Hope for Mental Health and Well Being Act of 2022; and H.R. 5218, Collaborate in an Orderly and Cohesive Manner Act.

Issues generally in the Affordable Care Act; issues related to insurance markets and stabilization, transparency, surprise billing, access to and payment for mental health care, and COVID-19 response in P.L. 117-103, the Consolidated Appropriations Act, 2022; H.R. 7666, Restoring Hope for Mental Health and Well-Being Act of 2022; and health care policies contained in and amendments offered to P.L. 117-2, the American Rescue Plan Act of 2021; P.L. 117-169, Inflation Reduction Act of 2021; H.R. 5218, Collaborate in an Orderly and Cohesive Manner Act.

Issues generally in the Affordable Care Act; issues related to insurance markets and stabilization, transparency, surprise billing, access to and payment for mental health care, and COVID-19 response in P.L. 117-103, the Consolidated Appropriations Act, 2022; H.R. 7666, Restoring Hope for Mental Health and Well-Being Act of 2022; and health care policies contained in and amendments offered to P.L. 117-2, the American Rescue Plan Act of 2021; P.L. 117-169, Inflation Reduction Act of 2021; H.R. 5218, Collaborate in an Orderly and Cohesive Manner Act.

H.R. 2255/ S.1024-Healthcare Workforce Resilience Act; H.R. 3648, Equal Access to Green cards for Legal Employment Act of 2021 or the EAGLE Act of 2021; and H.R. 3541/S. 1810, Conrad State 30 and Physician Access Reauthorization Act; policies contained in H.R. 5376, to provide for reconciliation pursuant to title II of S. Con. Res. 14.

General education around paid family, medical and sick leave issues; paid sick day policies in P.L. 117-2, the Consolidated Appropriations Act, 2021, H.R. 804/S. 248, the FAMILY Act; policies contained in H.R.3684, Infrastructure Investment and Jobs Act and H.R. 5376, Build Back Better Act.

General education around long term services and supports, home and community-based services issues, spousal impoverishment, Medicaid eligibility in Section 1115 waivers, Money Follows the Person program; home and community services policies in H.R. 5376, Build Back Better Act.

Policies that affect hospitals and skilled nursing facilities in P.L. 117-103, the Consolidated Appropriations Act, 2022,, H.R.3684, Infrastructure Investment and Jobs Act and H.R. 5376, to provide for reconciliation pursuant to title II of S. Con. Res. 14; various value-based payment models at the Centers for Medicare and Medicaid Innovations.

Issues generally related to the Orphan Drug Tax Credit, including provisions in H,R. 2623, Camerons Law and H.R. 5376, Build Back Better Act.

Issues related generally to: the Affordable Care Act, insurance markets/stabilization, transparency, surprise billing, access to and payment for mental health care, and COVID-19 response, including those contained in but not limited to policies in and amendments offered to S.Con.Res.5, setting forth the congressional budget for the United States Government for fiscal year 2021 and setting forth the appropriate budgetary levels for fiscal years 2022 through 2030, and P.L. 117-103, the Consolidated Appropriations Act, 2022; and health care policies contained in and amendments offered to P.L. 117-2, the American Rescue Plan Act of 2021. Policies contained in H.R.3684 - Infrastructure Investment and Jobs Act, and H.R. 5376, Build Back Better Act.

Issues related generally to: Medicare Advantage, Medicare Part D, and Medicaid managed care plans, including but not limited to policies related to social determinants of health, health equity, and maternal mortality, including policies contained in and amendments offered to S.Con.Res.5, setting forth the congressional budget for the United States Government for fiscal year 2021 and setting forth the appropriate budgetary levels for fiscal years 2022 through 2030; and policies contained in and amendments offered to P.L. 117-2, the American Rescue Plan Act of 2021. Policies contained in P.L. 117-7, to prevent across-the-board direct spending cuts, and for other purposes, and P.L. 117-71, Protecting Medicare and American Farmers from Sequester Cuts Act. Policies contained in H.R.3684 - Infrastructure Investment and Jobs Act, and H.R. 5376, Build Back Better Act.

Policies contained in H.R.3684, Infrastructure Investment and Jobs Act and H.R. 5376, Build Back Better Act.

General education around long term services and supports, home and community-based services issues, spousal impoverishment, Medicaid eligibility in Section 1115 waivers, Money Follows the Person program; home and community services policies in H.R. 5376, Build Back Better Act.

Policies that affect hospitals and skilled nursing facilities in P.L. 117-103, the Consolidated Appropriations Act, 2022,, H.R.3684, Infrastructure Investment and Jobs Act and H.R. 5376, to provide for reconciliation pursuant to title II of S. Con. Res. 14; various value-based payment models at the Centers for Medicare and Medicaid Innovation.

Issues generally related to biopharmaceutical drugs and drug development programs, including but not limited to drug pricing proposals, Medicaid payments, access to treatment through telehealth, and access to rare disease and gene therapy drugs. Policies contained in drug pricing proposals, including H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act and H.R. 19/S.2164, Lower Costs, More Cures Act of 2021, and in H.R.3684 - Infrastructure Investment and Jobs Act and H.R. 5376, Build Back Better Act. Policies contained in 85 FR 87000, Medicaid Program; Establishing Minimum Standards in Medicaid State Drug Utilization Review (DUR) and Supporting Value-Based Purchasing (VBP) for Drugs Covered in Medicaid, Revising Medicaid Drug Rebate and Third Party Liability (TPL) Requirements. H.R. 7489, Medicaid VBPs for Patients Act or the MVP Act.

H.R. 2255/ S.1024-Healthcare Workforce Resilience Act; H.R. 3648, Equal Access to Green cards for Legal Employment Act of 2021 or the EAGLE Act of 2021; and H.R. 3541/S. 1810, Conrad State 30 and Physician Access Reauthorization Act; policies contained in H.R. 5376, to provide for reconciliation pursuant to title II of S. Con. Res. 14.

Issues generally related to the Orphan Drug Tax Credit, including provisions in H,R. 2623, Camerons Law and H.R. 5376, Build Back Better Act.

Issues generally related to biopharmaceutical drugs and drug development programs, including but not limited to drug pricing proposals, Medicaid payments, and access to rare disease and gene therapy drugs. Policies contained in drug pricing proposals, including H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act and H.R. 19/S.2164, Lower Costs, More Cures Act of 2021, and in H.R.3684 - Infrastructure Investment and Jobs Act and H.R. 5376, Build Back Better Act. Policies contained in 85 FR 87000, Medicaid Program; Establishing Minimum Standards in Medicaid State Drug Utilization Review (DUR) and Supporting Value-Based Purchasing (VBP) for Drugs Covered in Medicaid, Revising Medicaid Drug Rebate and Third Party Liability (TPL) Requirements.

Policies that affect hospitals in P.L. 117-103, the Consolidated Appropriations Act, 2022, H.R.3684, Infrastructure Investment and Jobs Act and H.R. 5376, to provide for reconciliation pursuant to title II of S. Con. Res. 14.

Issues related generally to: Medicare Advantage, Medicare Part D, and Medicaid managed care plans, including but not limited to policies related to social determinants of health, health equity, and maternal mortality, including policies contained in and amendments offered to S.Con.Res.5, setting forth the congressional budget for the United States Government for fiscal year 2021 and setting forth the appropriate budgetary levels for fiscal years 2022 through 2030; and policies contained in and amendments offered to P.L. 117-2, the American Rescue Plan Act of 2021. Policies contained in P.L. 117-7, to prevent across-the-board direct spending cuts, and for other purposes, and P.L. 117-71, Protecting Medicare and American Farmers from Sequester Cuts Act. Policies contained in H.R.3684 - Infrastructure Investment and Jobs Act, and H.R. 5376, Build Back Better Act.

Policies contained in H.R.3684, Infrastructure Investment and Jobs Act and H.R. 5376, Build Back Better Act.

H.R. 2255/S.1024, Healthcare Workforce Resilience Act; H.R. 3648, Equal Access to Green cards for Legal Employment Act of 2021 or the EAGLE Act of 2021; H.R. 3541/S. 1810, Conrad State 30 and Physician Access Reauthorization Act; policies contained in H.R. 5376, to provide for reconciliation pursuant to title II of S. Con. Res. 14.

Issues related generally to: the Affordable Care Act, insurance markets/stabilization, transparency, surprise billing, access to and payment for mental health care, and COVID-19 response, including those contained in but not limited to policies in and amendments offered to S.Con.Res.5, setting forth the congressional budget for the United States Government for fiscal year 2021 and setting forth the appropriate budgetary levels for fiscal years 2022 through 2030, and P.L. 117-103, the Consolidated Appropriations Act, 2022; and health care policies contained in and amendments offered to P.L. 117-2, the American Rescue Plan Act of 2021. Policies contained in H.R.3684 - Infrastructure Investment and Jobs Act, H.R. 5376, Build Back Better Act; H.R. 7666, Restoring Hope for Mental Health and Well Being Act of 2022; and H.R. 5218, Collaborate in an Orderly and Cohesive Manner Act.

H.R. 2255/ S.1024-Healthcare Workforce Resilience Act; H.R. 3648, Equal Access to Green cards for Legal Employment Act of 2021 or the EAGLE Act of 2021; and H.R. 3541/S. 1810, Conrad State 30 and Physician Access Reauthorization Act; policies contained in H.R. 5376, to provide for reconciliation pursuant to title II of S. Con. Res. 14.

General education around long term services and supports, home and community-based services issues, spousal impoverishment, Medicaid eligibility in Section 1115 waivers, Money Follows the Person program; home and community services policies in H.R. 5376, Build Back Better Act.

Policies that affect hospitals and ambulatory surgery centers in P.L. 117-103, the Consolidated Appropriations Act, 2022, H.R.3684, Infrastructure Investment and Jobs Act and H.R. 5376, to provide for reconciliation pursuant to title II of S. Con. Res. 14.

Issues generally related to biopharmaceutical drugs and drug development programs, including, but not limited to: Orphan Drug Act incentives, including H.R. 1629/S.250, the Fairness in Orphan Drug Exclusivity Act; drug pricing proposals, including H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act and H.R. 19/S.2164, Lower Costs, More Cures Act of 2021; access to rare disease and gene therapy drugs; education and awareness of genetic rare bone disorders; FDA approvals of drugs designed to treat rare diseases, including gene therapies; and regulatory reforms generally, including but not limited to S. 3799, the PREVENT Pandemics Act, H.R. 6000, CURES 2.0, H.R. 6963, the Accelerated Approval Integrity Act of 2022, H.R. 6996, the Accelerating Access for Patients Act; H.R. 7667, Food and Drug Amendments of 2022, and S. 4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act. Issues pertaining to newborn screening and gene panel screening, including provisions of H.R. 482/S.350 , the Newborn Screening Saves Lives Reauthorization Act of 2021. Policies contained in and amendments offered to S.Con.Res.5, setting forth the congressional budget for the United States Government for fiscal year 2021 and setting forth the appropriate budgetary levels for fiscal years 2022 through 2030; and policies contained in and amendments offered to P.L. 117-2, the American Rescue Plan Act of 2021.

Issues generally related to biopharmaceutical drugs and drug development programs, including, but not limited to: Orphan Drug Act incentives, including H.R. 1629/S.250, the Fairness in Orphan Drug Exclusivity Act; drug pricing proposals, including H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act and H.R. 19/S.2164, Lower Costs, More Cures Act of 2021; access to rare disease and gene therapy drugs; FDA approvals of drugs designed to treat rare diseases, including gene therapies; and regulatory reforms generally, including but not limited to S. 3799, the PREVENT Pandemics Act, H.R. 6000, CURES 2.0, H.R. 6963, the Accelerated Approval Integrity Act of 2022, H.R. 6996, the Accelerating Access for Patients Act. Issues pertaining to newborn screening and gene panel screening, including provisions of H.R. 482/S.350 , the Newborn Screening Saves Lives Reauthorization Act of 2021. Policies contained in and amendments offered to S.Con.Res.5, setting forth the congressional budget for the United States Government for fiscal year 2021 and setting forth the appropriate budgetary levels for fiscal years 2022 through 2030; and policies contained in and amendments offered to P.L. 117-2, the American Rescue Plan Act of 2021.

Issues generally related to biopharmaceutical drugs and drug development programs, including, but not limited to: Orphan Drug Act incentives, including H.R. 1629/S.250, the Fairness in Orphan Drug Exclusivity Act; drug pricing proposals, including H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act and H.R. 19/S.2164, Lower Costs, More Cures Act of 2021; access to rare disease and gene therapy drugs; education and awareness of genetic rare bone disorders; FDA approvals of drugs designed to treat rare diseases, including gene therapies; and regulatory reforms generally, including but not limited to S. 3799, the PREVENT Pandemics Act, H.R. 6000, CURES 2.0, H.R. 6963, the Accelerated Approval Integrity Act of 2022, H.R. 6996, the Accelerating Access for Patients Act; H.R. 7667, Food and Drug Amendments of 2022, and S. 4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act. Issues pertaining to newborn screening and gene panel screening, including provisions of H.R. 482/S.350 , the Newborn Screening Saves Lives Reauthorization Act of 2021. Policies contained in and amendments offered to S.Con.Res.5, setting forth the congressional budget for the United States Government for fiscal year 2021 and setting forth the appropriate budgetary levels for fiscal years 2022 through 2030; and policies contained in and amendments offered to P.L. 117-2, the American Rescue Plan Act of 2021.

Issues generally related to biopharmaceutical drugs and drug development programs, including, but not limited to: Orphan Drug Act incentives, including H.R. 1629/S.250, the Fairness in Orphan Drug Exclusivity Act; drug pricing proposals, including H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act and H.R. 19/S.2164, Lower Costs, More Cures Act of 2021; access to rare disease and gene therapy drugs; FDA approvals of drugs designed to treat rare diseases, including gene therapies; and regulatory reforms generally, including but not limited to S. 3799, the PREVENT Pandemics Act, H.R. 6000, CURES 2.0, H.R. 6963, the Accelerated Approval Integrity Act of 2022, H.R. 6996, the Accelerating Access for Patients Act. Issues pertaining to newborn screening and gene panel screening, including provisions of H.R. 482/S.350 , the Newborn Screening Saves Lives Reauthorization Act of 2021. Policies contained in and amendments offered to S.Con.Res.5, setting forth the congressional budget for the United States Government for fiscal year 2021 and setting forth the appropriate budgetary levels for fiscal years 2022 through 2030; and policies contained in and amendments offered to P.L. 117-2, the American Rescue Plan Act of 2021.

Issues generally related to biopharmaceutical drugs and drug development programs, including, but not limited to: Orphan Drug Act incentives, including H.R. 1629/S.250, the Fairness in Orphan Drug Exclusivity Act; drug pricing proposals, including H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act and H.R. 19/S.2164, Lower Costs, More Cures Act of 2021; access to rare disease and gene therapy drugs; FDA approvals of drugs designed to treat rare diseases, including gene therapies; and regulatory reforms generally, including but not limited to S. 3799, the PREVENT Pandemics Act, H.R. 6000, CURES 2.0, H.R. 6963, the Accelerated Approval Integrity Act of 2022, H.R. 6996, the Accelerating Access for Patients Act. Issues pertaining to newborn screening and gene panel screening, including provisions of H.R. 482/S.350 , the Newborn Screening Saves Lives Reauthorization Act of 2021. Policies contained in and amendments offered to S.Con.Res.5, setting forth the congressional budget for the United States Government for fiscal year 2021 and setting forth the appropriate budgetary levels for fiscal years 2022 through 2030; and policies contained in and amendments offered to P.L. 117-2, the American Rescue Plan Act of 2021.

Issues generally related to biopharmaceutical drugs and drug development programs, including, but not limited to: Orphan Drug Act incentives, including H.R. 1629/S.250, the Fairness in Orphan Drug Exclusivity Act; drug pricing proposals, including H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act and H.R. 19/S.2164, Lower Costs, More Cures Act of 2021; access to rare disease and gene therapy drugs; education and awareness of genetic rare bone disorders; FDA approvals of drugs designed to treat rare diseases, including gene therapies; and regulatory reforms generally, including but not limited to S. 3799, the PREVENT Pandemics Act, H.R. 6000, CURES 2.0, H.R. 6963, the Accelerated Approval Integrity Act of 2022, H.R. 6996, the Accelerating Access for Patients Act; H.R. 7667, Food and Drug Amendments of 2022, and S. 4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act. Issues pertaining to newborn screening and gene panel screening, including provisions of H.R. 482/S.350 , the Newborn Screening Saves Lives Reauthorization Act of 2021. Policies contained in and amendments offered to S.Con.Res.5, setting forth the congressional budget for the United States Government for fiscal year 2021 and setting forth the appropriate budgetary levels for fiscal years 2022 through 2030; and policies contained in and amendments offered to P.L. 117-2, the American Rescue Plan Act of 2021.

Issues generally related to biopharmaceutical drugs and drug development programs, including but not limited to drug pricing proposals, Medicaid payments, access to treatment through telehealth, and access to rare disease and gene therapy drugs. Policies contained in drug pricing proposals, including H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act and H.R. 19/S.2164, Lower Costs, More Cures Act of 2021. Policies contained in 85 FR 87000, Medicaid Program; Establishing Minimum Standards in Medicaid State Drug Utilization Review (DUR) and Supporting Value-Based Purchasing (VBP) for Drugs Covered in Medicaid, Revising Medicaid Drug Rebate and Third Party Liability (TPL) Requirements. H.R. 7489, Medicaid VBPs for Patients Act or the MVP Act.

Issues generally related to biopharmaceutical drugs and drug development programs, including but not limited to drug pricing proposals, Medicaid payments, access to treatment through telehealth, and access to rare disease and gene therapy drugs. Policies contained in drug pricing proposals, including H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act and H.R. 19/S.2164, Lower Costs, More Cures Act of 2021, and in H.R.3684 - Infrastructure Investment and Jobs Act and H.R. 5376, Build Back Better Act. Policies contained in 85 FR 87000, Medicaid Program; Establishing Minimum Standards in Medicaid State Drug Utilization Review (DUR) and Supporting Value-Based Purchasing (VBP) for Drugs Covered in Medicaid, Revising Medicaid Drug Rebate and Third Party Liability (TPL) Requirements. H.R. 7489, Medicaid VBPs for Patients Act or the MVP Act.

Issues generally related to biopharmaceutical drugs and drug development programs, including but not limited to drug pricing proposals, Medicaid payments, access to treatment through telehealth, and access to rare disease and gene therapy drugs. Policies contained in drug pricing proposals, including H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act and H.R. 19/S.2164, Lower Costs, More Cures Act of 2021. Policies contained in 85 FR 87000, Medicaid Program; Establishing Minimum Standards in Medicaid State Drug Utilization Review (DUR) and Supporting Value-Based Purchasing (VBP) for Drugs Covered in Medicaid, Revising Medicaid Drug Rebate and Third Party Liability (TPL) Requirements. H.R. 7489, Medicaid VBPs for Patients Act or the MVP Act.

Issues generally in the Affordable Care Act; issues related to insurance markets and stabilization, transparency, surprise billing, access to and payment for mental health care, and COVID-19 response in P.L. 117-103, the Consolidated Appropriations Act, 2022; H.R. 7666, Restoring Hope for Mental Health and Well-Being Act of 2022; and health care policies contained in and amendments offered to P.L. 117-2, the American Rescue Plan Act of 2021; P.L. 117-169, Inflation Reduction Act of 2021; H.R. 5218, Collaborate in an Orderly and Cohesive Manner Act.

Issues generally in the Affordable Care Act; issues related to insurance markets and stabilization, transparency, surprise billing, access to and payment for mental health care, and COVID-19 response in P.L. 117-103, the Consolidated Appropriations Act, 2022; H.R. 7666, Restoring Hope for Mental Health and Well-Being Act of 2022; and health care policies contained in and amendments offered to P.L. 117-2, the American Rescue Plan Act of 2021; P.L. 117-169, Inflation Reduction Act of 2021; H.R. 5218, Collaborate in an Orderly and Cohesive Manner Act.

Issues related generally to: the Affordable Care Act, insurance markets/stabilization, transparency, surprise billing, access to and payment for mental health care, and COVID-19 response, including those contained in but not limited to policies in and amendments offered to S.Con.Res.5, setting forth the congressional budget for the United States Government for fiscal year 2021 and setting forth the appropriate budgetary levels for fiscal years 2022 through 2030, and P.L. 117-103, the Consolidated Appropriations Act, 2022; and health care policies contained in and amendments offered to P.L. 117-2, the American Rescue Plan Act of 2021. Policies contained in H.R.3684 - Infrastructure Investment and Jobs Act, H.R. 5376, Build Back Better Act; H.R. 7666, Restoring Hope for Mental Health and Well Being Act of 2022; and H.R. 5218, Collaborate in an Orderly and Cohesive Manner Act.

Issues generally related to biopharmaceutical drugs and drug development programs, including, but not limited to: Orphan Drug Act incentives, including H.R. 1629/S.250, the Fairness in Orphan Drug Exclusivity Act; drug pricing proposals, including H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act and H.R. 19/S.2164, Lower Costs, More Cures Act of 2021; access to rare disease and gene therapy drugs; education and awareness of genetic rare bone disorders; FDA approvals of drugs designed to treat rare diseases, including gene therapies; and regulatory reforms generally, including but not limited to S. 3799, the PREVENT Pandemics Act, H.R. 6000, CURES 2.0, H.R. 6963, the Accelerated Approval Integrity Act of 2022, H.R. 6996, the Accelerating Access for Patients Act; H.R. 7667, Food and Drug Amendments of 2022, and S. 4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act. Issues pertaining to newborn screening and gene panel screening, including provisions of H.R. 482/S.350 , the Newborn Screening Saves Lives Reauthorization Act of 2021. Policies contained in and amendments offered to S.Con.Res.5, setting forth the congressional budget for the United States Government for fiscal year 2021 and setting forth the appropriate budgetary levels for fiscal years 2022 through 2030; and policies contained in and amendments offered to P.L. 117-2, the American Rescue Plan Act of 2021.